Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

New generic versions of semaglutide in Canada are likely to mark the start of a decline in Novo Nordisk’s international revenue from Ozempic and Wegovy. The article signals pricing and volume pressure for the drug franchise rather than an immediate shock. This is a modestly negative development for Novo, with limited near-term market impact.

Analysis

New generic versions of semaglutide in Canada are likely to mark the start of a decline in Novo Nordisk’s international revenue from Ozempic and Wegovy. The article signals pricing and volume pressure for the drug franchise rather than an immediate shock. This is a modestly negative development for Novo, with limited near-term market impact.